TG Therapeutics to Present at the Jefferies 2019 Healthcare Conference
04 June 2019 - 9:30PM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael
S. Weiss, the Company’s Executive Chairman and Chief Executive
Officer, will present at the Jefferies 2019 Healthcare Conference,
being held at the Grand Hyatt Hotel in New York City. The
presentation is scheduled to take place on Wednesday, June 5, 2019
at 9:00 AM ET.
A live webcast of this presentation will be
available on the Events page, located within the Investors &
Media section, of the Company’s website at
http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical
company focused on the acquisition, development and
commercialization of novel treatments for B-cell malignancies and
autoimmune diseases. Currently, the company is developing two
therapies targeting hematological malignancies and autoimmune
diseases. Ublituximab (TG-1101) is a novel, glycoengineered
monoclonal antibody that targets a specific and unique epitope on
the CD20 antigen found on mature B-lymphocytes. TG
Therapeutics is also developing umbralisib (TGR-1202), an
oral, once-daily inhibitor of PI3K-delta. Umbralisib uniquely
inhibits CK1-epsilon, which may allow it to overcome certain
tolerability issues associated with first generation PI3K-delta
inhibitors. Both ublituximab and umbralisib, or the combination of
which is referred to as "U2", are in Phase 3 clinical development
for patients with hematologic malignancies, with ublituximab also
in Phase 3 clinical development for Multiple Sclerosis.
Additionally, the Company has recently brought its anti-PD-L1
monoclonal antibody, TG-1501, its covalently-bound Bruton’s
Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its
anti-CD47/CD19 bispecific antibody, TG-1801, into Phase 1
development. TG Therapeutics is headquartered
in New York City.
CONTACT: |
|
Jenna Bosco |
|
Senior Vice President, |
|
Corporate Communications |
|
TG Therapeutics, Inc. |
|
Telephone: 212.554.4351 |
|
Email: ir@tgtxinc.com |
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2024 to May 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From May 2023 to May 2024